125 related articles for article (PubMed ID: 19591407)
1. [Business administration of PET facilities: a cost analysis of three facilities utilizing delivery FDG].
Mitsutake N; Oku S; Fujii R; Furui Y; Yasunaga H
Kaku Igaku; 2008 May; 45(2):119-23. PubMed ID: 19591407
[TBL] [Abstract][Full Text] [Related]
2. [Business administration of PET facilities: a nationwide survey for prices of PET screening and a cost analysis of three facilities].
Mitsutake N; Fujii R; Oku S; Furui Y; Yasunaga H
Kaku Igaku; 2007 May; 44(2):125-9. PubMed ID: 18240584
[TBL] [Abstract][Full Text] [Related]
3. The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers.
Berger M; Gould MK; Barnett PG
AJR Am J Roentgenol; 2003 Aug; 181(2):359-65. PubMed ID: 12876011
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
6. Costs of F-18-FDG PET: experience with a satellite concept.
Lottes G; Gorschlüter P; Kuwert T; Adam D; Schober O
Nuklearmedizin; 1998 Aug; 37(5):159-64; discussion 165. PubMed ID: 9728342
[TBL] [Abstract][Full Text] [Related]
7. The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma.
Yen RF; Yen MF; Hong RL; Tzen KY; Chien CR; Chen TH
Acad Radiol; 2009 Jan; 16(1):54-60. PubMed ID: 19064212
[TBL] [Abstract][Full Text] [Related]
8. [Impact of FDG-PET on radiation therapy: economic results of a STIC study].
Remonnay R; Morelle M; Giammarile F; Pommier P; Carrère MO
Cancer Radiother; 2009 Jul; 13(4):313-7. PubMed ID: 19493691
[TBL] [Abstract][Full Text] [Related]
9. The cost-effective use of 18F-FDG PET in the presurgical evaluation of medically refractory focal epilepsy.
O'Brien TJ; Miles K; Ware R; Cook MJ; Binns DS; Hicks RJ
J Nucl Med; 2008 Jun; 49(6):931-7. PubMed ID: 18483097
[TBL] [Abstract][Full Text] [Related]
10. [Costs of F-18-FDG PET with a satellite concept: update].
Lottes G; Schober O
Nuklearmedizin; 2000; 39(3):72-6. PubMed ID: 10834194
[TBL] [Abstract][Full Text] [Related]
11. Activity-based costing evaluation of a [(18)F]-fludeoxyglucose positron emission tomography study.
Krug B; Van Zanten A; Pirson AS; Crott R; Borght TV
Health Policy; 2009 Oct; 92(2-3):234-43. PubMed ID: 19446356
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of dual-head 18F-fluorodeoxyglucose PET for the detection of recurrent laryngeal cancer.
Bongers V; Hobbelink MG; van Rijk PP; Hordijk GJ
Cancer Biother Radiopharm; 2002 Jun; 17(3):303-6. PubMed ID: 12136522
[TBL] [Abstract][Full Text] [Related]
13. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
[TBL] [Abstract][Full Text] [Related]
15. Is a methodology available that accurately measures the cost of an FDG-PET study?
Krug B; Pirson AS; Crott R; Vander Borght T
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):625-627. PubMed ID: 17160411
[No Abstract] [Full Text] [Related]
16. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
[TBL] [Abstract][Full Text] [Related]
19. Marginal cost of operating a positron emission tomography center in a regulatory environment.
Chuck A; Jacobs P; Logus JW; St Hilaire D; Chmielowiec C; McEwan AJ
Int J Technol Assess Health Care; 2005; 21(4):442-51. PubMed ID: 16262966
[TBL] [Abstract][Full Text] [Related]
20. Activity-based costing evaluation of [18F]-fludeoxyglucose production.
Krug B; Van Zanten A; Pirson AS; Crott R; Vander Borght T
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):80-8. PubMed ID: 17891498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
